-
公开(公告)号:US08889861B2
公开(公告)日:2014-11-18
申请号:US13574488
申请日:2011-01-24
申请人: Benjamin Mark Skead , Christopher Peter Worrall , Jonathan Charles Christian Atherton , Julian Scott Northen , Philippe Fernades
发明人: Benjamin Mark Skead , Christopher Peter Worrall , Jonathan Charles Christian Atherton , Julian Scott Northen , Philippe Fernades
IPC分类号: C07D473/00 , C07C59/265 , C07D473/16 , G01P5/07 , C07C65/05 , G01F1/115 , C07C309/04 , C07C59/255 , C07C51/41 , C07C309/29 , C07C59/245 , C07C303/32 , C07C57/145 , G01P3/48 , C07C57/15 , A61K31/52
CPC分类号: C07D473/16 , A61K31/52 , C07B2200/13 , C07C51/412 , C07C57/145 , C07C57/15 , C07C59/245 , C07C59/255 , C07C59/265 , C07C65/05 , C07C303/32 , C07C309/04 , C07C309/29 , G01F1/115 , G01P3/4802 , G01P5/07
摘要: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
摘要翻译: 本发明涉及嘌呤衍生物的新结晶形式,其具有优异的抗肿瘤活性。 本发明还涉及含有所述结晶形式作为活性成分的药物组合物及其在预防或治疗疾病中的用途。 本发明还涉及制备结晶形式的方法。
-
公开(公告)号:US20130072504A1
公开(公告)日:2013-03-21
申请号:US13574488
申请日:2011-01-24
申请人: Benjamin Mark Skead , Christopher Peter Worrall , Jonathan Charles Christian Atherton , Julian Scott Northen , Philippe Fernades
发明人: Benjamin Mark Skead , Christopher Peter Worrall , Jonathan Charles Christian Atherton , Julian Scott Northen , Philippe Fernades
IPC分类号: A61K31/52 , C07D473/16 , C07C309/04 , C07C59/255 , C07C59/265 , C07C309/29 , C07C303/32 , C07C57/145 , C07C65/05 , C07C57/15 , C07C59/245 , C07C51/41 , C07D473/34
CPC分类号: C07D473/16 , A61K31/52 , C07B2200/13 , C07C51/412 , C07C57/145 , C07C57/15 , C07C59/245 , C07C59/255 , C07C59/265 , C07C65/05 , C07C303/32 , C07C309/04 , C07C309/29 , G01F1/115 , G01P3/4802 , G01P5/07
摘要: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.
-
公开(公告)号:US5892093A
公开(公告)日:1999-04-06
申请号:US796358
申请日:1997-02-07
IPC分类号: C07C255/41 , C07C255/03
CPC分类号: C07C253/34 , C07C255/41 , C07B2200/07
摘要: A reproducible process for preparing a substantially single enantiomer (R or S) of 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexanoic acid, or an analogue thereof, thereby providing single enantiomer acid for the first time, proceeds by means of a classical salt resolution employing a resolving agent selected from an enantiomer (R or S) of a 1-arylalkylamine and (-)-quinine, and provides novel salts that are readily convertible to verapamil.
摘要翻译: 制备4-氰基-4-(3,4-二甲氧基苯基)-5-甲基己酸或其类似物的基本上单一的对映异构体(R或S)的再现方法,从而首次提供单一对映异构体酸 通过使用选自1-芳基烷基胺和( - ) - 奎宁的对映异构体(R或S)的拆分剂的经典盐分解,并提供易于转化为维拉帕米的新型盐。
-
公开(公告)号:US07034028B2
公开(公告)日:2006-04-25
申请号:US10362784
申请日:2001-08-31
IPC分类号: A61K31/44 , A61K31/47 , A61K31/445 , A61K31/495
CPC分类号: A61K31/49
摘要: A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine.
摘要翻译: 治疗受试者的炎性疾病或自身免疫性疾病的方法包括施用甲氟喹。
-
公开(公告)号:US06951943B2
公开(公告)日:2005-10-04
申请号:US10620396
申请日:2003-07-16
申请人: Benjamin Mark Skead , Nicholas David Tyrrell , Stephen Wilfred Jones , Michael Handforth Brookes
发明人: Benjamin Mark Skead , Nicholas David Tyrrell , Stephen Wilfred Jones , Michael Handforth Brookes
IPC分类号: C07B61/00 , C07C229/36 , C07D213/81 , C07D311/96 , C07D471/04 , C07D213/72
CPC分类号: C07D213/81 , C07D311/96 , C07D471/04
摘要: A process for the preparation of a class of phenylalanine enamide derivatives is described: wherein: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a linker group selected from —N(R4)— [where R4 is a hydrogen atom or an optionally substituted straight or branched C1-6alkyl group], —CON(R4)—, or —S(O)2N(R4)—; R1 is a carboxylic acid (—CO2H) or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; Rx, Ry and Rz which may be the same or different is each an atom or group -L1(Alk1)n(R3)v; and the salts, solvates, hydrates and N-oxides thereof; which comprises reacting a compound of formula (2): wherein: Qa is a group —N(R4)H; and the salts, solvates, hydrates and N-oxides thereof; with a compound Ar1W wherein W is a group selected from X1(wherein X1 is a leaving atom or group), —COX2 (wherein X2 is a halogen atom or a —OH group) or —SO2X3 (in which X3 is a halogen atom).
摘要翻译: 描述了制备一类苯丙氨酸烯酰胺衍生物的方法:其中:Ar 1是任选取代的芳族或杂芳族基团; L 2是选自-N(R 4) - 的连接基团,其中R 4是氢原子或任选取代的直链或 支链C 1-6烷基],-CON(R 4) - 或-S(O)2 N(R' > 4 SUP>) - ; R 1是羧酸(-CO 2 H 2 H)或其衍生物或生物试剂; R 2是氢原子或C 1-6烷基; R“X”,“R”和“Z”可以相同或不同,各自为原子或基团-L 1, (R 1)3,其中R 1,R 2,R 3,R 3,R 3, 及其盐,溶剂合物,水合物及其N-氧化物; 其包括使式(2)的化合物与其反应:其中:Q是基团-N(R 4 O)H; 及其盐,溶剂合物,水合物及其N-氧化物; 与其中W是选自X 1(其中X 1是离去的原子或基团)的基团的化合物Ar 1,-COX (其中X 2是卤素原子或-OH基团)或-SO 2 X 3(其中X 2是卤素原子或-OH基团)或-SO 2 X 3 其中X 3是卤素原子)。
-
公开(公告)号:US5994548A
公开(公告)日:1999-11-30
申请号:US849418
申请日:1997-04-25
IPC分类号: C07B57/00 , C07D211/60 , C07D211/30
CPC分类号: C07D211/60
摘要: Levobupivacaine or an analogue thereof is prepared by reaction with a tartaric acid resolving agent in a solvent, in the presence of water and/or less 0.5 equivalents of the resolving agent.
摘要翻译: PCT No.PCT / GB95 / 02513 Sec。 371日期1997年04月25日 102(e)日期1997年4月25日PCT提交1995年10月23日PCT公布。 WO96 / 12699 PCT出版物 日期1996年5月2日左布比卡因或其类似物通过在溶剂中,在水和/或较少0.5当量的拆分剂的存在下与酒石酸拆分剂反应来制备。
-
-
-
-
-